Recharging the “Immune Battery” in Heart Failure
Written by Georgia Truman (MSc), Molecular and Cellular Biology. Reviewed by Dr. Siobhan Mitchell (PhD), Neuroscience.
Heart failure with preserved ejection fraction (HFpEF) is characterised by systemic inflammation, exercise intolerance, and limited treatment options. Increasing evidence suggests that immune cell mitochondrial dysfunction contributes directly to the chronic inflammatory burden that defines the condition. This trial investigated whether restoring immune cell energetics could address this upstream metabolic deficit.
What you'll learn:
How mitochondrial dysfunction in immune cells contributes to inflammation in HFpEF
Why peripheral blood mononuclear cells provide a window into systemic bioenergetic health
The effects of 4 weeks of Mitoquinol supplementation on immune cell respiration
Clinical implications of restoring spare respiratory capacity in chronic inflammatory disease
How is mitochondrial function impacted in heart failure patients?
HFpEF is increasingly understood as a systemic disorder rather than a purely cardiac condition. Alongside preserved ejection fraction, patients exhibit persistent low‑grade inflammation that is closely linked to cellular energetic failure. Immune cells in HFpEF patients display impaired oxidative phosphorylation, reduced ATP production, and limited flexibility to shift metabolic states in response to demand.
Without adequate mitochondrial energy reserves, immune cells struggle to complete the resolution phase of inflammation. Rather than cycling through activation and recovery, these cells remain chronically activated, perpetuating inflammatory signalling and reinforcing disease progression.
Why do immune cells provide a window into cellular function?
To assess whether mitochondrial dysfunction represents a modifiable target, investigators examined peripheral blood mononuclear cells (PBMCs), which can be sampled non‑invasively and whose mitochondrial activity can be quantified directly using high‑resolution respirometry.
In HFpEF, PBMC mitochondrial dysfunction closely mirrors broader systemic energetic impairment. Because immune cells both reflect and actively regulate inflammatory tone, improvements in their bioenergetics offer insight into whether an intervention is addressing root metabolic dysfunction rather than simply suppressing inflammatory markers.
How does Mitoquinol influence the energy status of immune cells?
In a 4‑week double‑blind, placebo‑controlled crossover trial, participants with HFpEF received Mitoquinol supplementation before undergoing serial assessments of PBMC mitochondrial function. This design allowed each individual to serve as their own control, strengthening inference regarding treatment effects.
Mitoquinol was investigated for its ability to stabilise mitochondrial respiration in this energetically constrained cellular environment. By reducing oxidative stress at the inner mitochondrial membrane, Mitoquinol preserves electron transport chain integrity and supports oxidative phosphorylation across multiple respiratory states.
These include basal respiration under resting conditions, maximal respiratory capacity during energetic stress, and spare respiratory capacity — the reserve that determines how effectively a cell can respond to acute inflammatory or metabolic demand.
Following supplementation, basal PBMC respiration increased from 66.5 to 106.4 pmol/min (P = 0.002), while maximal respiration rose from 89.2 to 279.7 pmol/min (P = 0.004). These improvements represent a substantial restoration of mitochondrial output in cells that were operating close to energetic failure at baseline.
What does spare respiratory capacity mean for the patient?
Spare respiratory capacity reflects the energetic buffer available beyond baseline metabolic demand. Prior to intervention, HFpEF patients exhibited critically limited reserve, leaving immune cells poorly equipped to respond to physiological or inflammatory stress.
Following Mitoquinol supplementation, spare respiratory capacity increased more than seven‑fold (from 22.8 to 173.3 pmol/min). From a clinical perspective, immune cells with restored reserve are better able to mount appropriate inflammatory responses and, crucially, resolve them efficiently — reducing the chronic immune activation that drives symptom burden and disease progression in HFpEF.
What are the practitioner takeaways for HFpEF?
HFpEF lacks disease‑modifying therapies that directly address its inflammatory and metabolic underpinnings. The magnitude of immune cell bioenergetic restoration observed with Mitoquinol positions mitochondrial redox balance as a viable upstream therapeutic target.
Although whether these cellular improvements translate into symptomatic or functional benefit remains to be tested in larger trials, the mechanistic signal is clear: immune dysfunction in HFpEF is not fixed. Instead, it appears at least partially reversible through interventions that restore mitochondrial energetic capacity.
Read the full article: A mitochondrial‑targeted ubiquinol improves immune cell bioenergetics in HFpEF – American Physiological Society DOI: 10.1152/physiol.2024.39.S1.1473
